FDA Grants Early Approval To Daraxonrasib Pancreatic Cancer Drug With Survival Benefit
44m
Breaking
3
The U.S. Food and Drug Administration on Wednesday, August 26, 2026, granted expedited approval to daraxonrasib, sold as Rasonque, for advanced metastatic pancreatic cancer after a trial showed a survival benefit. NPR
